Haloperidol (Haloperidol Decanoate EP Impurity G)(CAS: 52-86-8)

Haloperidol Decanoate EP Impurity G (CAS: 52-86-8) must comply with the regulations set by the European Chemicals Agency (REACH) for the registration of chemicals and their safe handling. The US FDA and EPA have specific guidelines for the pharmaceutical industry, including the safe storage and disposal of this compound. It is also important to follow the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) for safety data sheets (SDS) and labeling purposes.

In the synthesis of Haloperidol Decanoate, alternative reagents such as 2-bromobutane and N,N-dimethylbenzylamine can be used as substitutes. These alternatives can provide similar functionalities and can be chosen based on the specific requirements of the synthesis process, such as reactivity and cost.

The market for Haloperidol Decanoate, with impurity G, shows a steady demand driven by its use as an antipsychotic drug. Recent research trends focus on the development of more effective and safer formulations. Additionally, there is an increasing interest in understanding the pharmacokinetics and therapeutic effects of this compound, as well as exploring its potential in combination therapies.

Waste containing Haloperidol Decanoate EP Impurity G (CAS: 52-86-8) should be collected in designated storage areas and disposed of through professional waste disposal services. Incineration is often the preferred method due to the hazardous nature of the compound. Environmental protection measures include proper containment to prevent leakage and adherence to local and international environmental regulations to minimize ecological impact.